25
Participants
Start Date
May 14, 2018
Primary Completion Date
October 19, 2021
Study Completion Date
October 19, 2021
Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562
Three different combination are being tested. Each cohort has different combination
Rigshospitalet, København Ø
Haukeland University Hospital, Bergen
VejleSygehus, Vejle
Tampere University Hospital, Tampere
The Norwegian Radium Hospital, Oslo
Gynecologic Cancer Intergroup (GCIG)
OTHER
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
OTHER